Purpose: To report a case of deferoxamine-induced maculopathy and present the use of multimodal retinal imaging to study this disease entity.
Methods: This is an observational case report of one patient. Multimodal imaging with fundus autofluorescence, infrared imaging, and spectral domain optical coherence tomography was used to investigate the macular changes induced by deferoxamine toxicity.
Results: A 53-year-old man with history of β-thalassemia presented with decreased vision in both eyes 1 month after initiating deferoxamine therapy. Infrared imaging showed areas of increased stippled infrared intensity through the macula. Fundus autofluorescence revealed diffuse areas of stippled hyperautofluorescence and hypoautofluorescence. Spectral domain optical coherence tomography changes included disruption of the ellipsoid zone, attenuation of the photoreceptors, and deposits within the retinal pigment epithelium.
Conclusion: A case of deferoxamine-induced maculopathy was described and the use of multimodal retinal imaging to study this disease entity was presented.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4221805 | PMC |
| http://dx.doi.org/10.1097/ICB.0000000000000059 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Deferoxamine-induced electronegative ERG responses.
Doc Ophthalmol
August 2018
Department of Ophthalmology, Columbia University, New York, NY, USA.
Purpose: To report a case of deferoxamine-induced retinopathy characterized by electroretinography (ERG), optical coherence tomography angiography (OCT-A), and other multimodal imaging.
Methods: This is an observational case report of one patient. Full-field ERG was performed.
Multimodal imaging in a case of deferoxamine-induced maculopathy.
Retin Cases Brief Rep
June 2015
*Department of Ophthalmology, University of Southern California, Los Angeles, California; †Edward S. Harkness Eye Institute, College of Physicians and Surgeons, Columbia University, New York, New York; ‡Deparment of Pathology and Cell Biology, College of Physicians and Surgeons, Columbia University, New York, New York; §Department of Ophthalmology, Weill Cornell Medical College, New York, New York; and ¶Barbara and Donald Jonas Laboratory of Stem Cell and Regenerative Medicine, College of Physicians and Surgeons, Columbia University, New York, New York.
Purpose: To report a case of deferoxamine-induced maculopathy and present the use of multimodal retinal imaging to study this disease entity.
Methods: This is an observational case report of one patient. Multimodal imaging with fundus autofluorescence, infrared imaging, and spectral domain optical coherence tomography was used to investigate the macular changes induced by deferoxamine toxicity.
Spectral domain optical coherence tomography findings in early deferoxamine maculopathy: report of two cases.
Retin Cases Brief Rep
June 2015
Departments of *Ophthalmology, and †Hematology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium.
Purpose: To describe spectral domain optical coherence tomography features in two cases of early deferoxamine induced retinal toxicity.
Methods: Two patients complained of sudden bilateral visual loss and dyschromatopsia. Both suffered from acute myelocytic leukemia with severe aplastic anemia and were treated with intravenous deferoxamine for 1 month.
The expanded clinical spectrum of deferoxamine retinopathy.
Ophthalmology
January 2002
Department of Ophthalmology, Boston University School of Medicine, DOB-10 720 Harrison Avenue, Boston, MA 02118, USA.
Objective: To describe early and unusual features in 16 patients with deferoxamine-induced retinal toxicity and to assess the role of diagnostic tests in the diagnosis and management of patients with the disorder.
Design: Retrospective, observational case series.
Participants: Sixteen patients with deferoxamine retinopathy identified from members of the Vitreous, Retina, and Macula societies of the United States.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!